Govt must indemnify vaccine makers against all lawsuits: Adar Poonawalla



Vaccine manufacturers need to have protection against all lawsuits for their vaccines especially during a pandemic, Serum Institute of India (SII) Chief Executive Officer Adar Poonawalla has said.


He also said that the vaccine makers are going to propose this to the government, while speaking at a virtual panel on the challenges of developing a Covid-19 vaccine at the Carnegie India’s Global Technology Summit on Friday.



“We need to have the government indemnify manufacturers, especially vaccine manufacturers, against all lawsuits. In fact, COVAX and other countries have already started talking about that,” Poonawalla said.


It is because when frivolous claims come up, and something is blown out of proportion in the media, skepticism sets in that definitely something can happen due to the vaccine and to dispel that, the government needs to step in to spread the right information, he added.


“..the government can act, the US, for example, has in fact invoked a law, to say that during a pandemic, and this is especially important only during a pandemic, to indemnify vaccine manufacturers against lawsuits for severe adverse effects or any other frivolous claims which may come about, because that adds to the fear and also will bankrupt vaccine manufacturers or distract them if they have to just all day fight lawsuits and explain to the media what is happening,” Poonawalla said.


These are a few things that the government can do and that is what the vaccine manufacturers are going to propose, he added.


Last month, Serum had rejected charges that a 40-year-old man who took part in the ‘Covishield’ vaccine trial in Chennai had levelled against the company, alleging serious side effects, including a virtual neurological breakdown and impairment of cognitive functions.


He had also sought Rs 5 crore compensation in a legal notice to Serum and others, besides seeking a halt on the trial.


Refuting the charges, Serum had said, “It is evident that the intention behind spreading of such malicious information is an oblique pecuniary motive. The Serum Institute of India, will seek damages in excess of Rs 100 crore for the same and will defend such malicious claims”.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor





Source link

Leave a Comment

Your email address will not be published. Required fields are marked *